" /> Cyclophosphamide/Epirubicin/Prednisone/Rituximab/Vincristine Regimen - CISMeF





Preferred Label : Cyclophosphamide/Epirubicin/Prednisone/Rituximab/Vincristine Regimen;

NCIt synonyms : Rituximab-Cyclophosphamide-Epirubicin-Oncovin-Prednisone Regimen; Cyclophosphamide/Epirubicin/Prednisone/Rituximab/Vincristine; Cyclophosphamide-Epirubicin-Prednisone-Rituximab-Vincristine; Cyclophosphamide-Epirubicin-Prednisone-Rituximab-Vincristine Regimen; R-CEOP90 Regimen;

NCIt related terms : R-CEOP90 (rituximab-blit); R-CEOP90 (rituximab-pvvr); R-CEOP90 (rituximab-rixi); R-CEOP90 (rituximab-rite); R-CEOP90 (rituximab-rixa); R-CEOP90 (rituximab-abbs); R-CEOP90; R-CEOP90 (rituximab-arrx);

NCIt definition : A regimen consisting of rituximab, cyclophosphamide, epirubicin, vincristine and prednisone that can be used to treat diffuse large B-cell lymphoma (DLBCL).;

NCI Metathesaurus CUI : CL1664732;

Codes from synonyms : 127926; 128554; 128711; 127769; 70112; 128397; 128240; 128083;

Détails


Vous pouvez consulter :


Nous contacter.
29/07/2025


[Accueil] [Haut de page]

© CHU de Rouen. Toute utilisation partielle ou totale de ce document doit mentionner la source.